OVERVIEW

Twelve checkpoint inhibitor therapies have been approved since 2011 in a wide variety of cancers, including tumor-agnostic indications for adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient cancer. Immune checkpoint blockade leads to a new spectrum of dysimmune toxicity requiring collaboration between oncologist providers and specialists to improve the understanding of the mechanism, diagnosis, and management of irAEs.

Specialists in dermatology, endocrinology, gastroenterology, oncology, pulmonology, rheumatology/ immunology, nurses, nurse practitioners, physician assistants and residents/ fellows are invited to attend.

LEARNING OBJECTIVES

As a result of attending the course, the participant will be able to:

• Describe the mechanism of action associated with checkpoint inhibitor therapies and the biologics used in the treatment of immune-related adverse events.
• Identify the spectrum of immune-related adverse events that can occur with immune checkpoint inhibitor therapies.
• Implement assessment criteria, diagnostic testing, and interventions to improve early identification and management of immune-related AEs.
• Recognize the importance and necessity of the multidisciplinary approach in treatment of immune-related adverse events.

ACCREDITATION

In support of improving patient care, Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME).

Cleveland Clinic Foundation Center for Continuing Education designates this live activity for a maximum of 13.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.